Skip to main content
TipRanks
Go Ultimate75% OFF

Futura Medical (GYX) AI Stock Analysis

1 Followers
DE:GYX

Futura Medical

(Frankfurt:GYX)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetZero debt reduces solvency pressure and avoids interest obligations that could further weaken results during loss-making periods. This gives Futura greater financial flexibility over the next several quarters, although it does not remove the need to improve cash generation.
Negative Factors
Sharp revenue contractionA roughly 79% annual revenue decline signals severe weakness in current commercial performance and makes near-term earnings recovery less predictable. Continued contraction would reduce the scale available to absorb operating costs and could constrain investment in product commercialisation.

Futura Medical (GYX) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%DE:GYX-50.00%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 878.87K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.4
Beta (1Y)
1.38
Revenue Growth
-71.75%
EPS Growth
61.79%
Country
Germany
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Futura Medical Business Overview & Revenue Model

Company Description

Futura Medical plc operates as a pharmaceutical firm specializing in the creation and advancement of consumer healthcare products. The company primarily targets the sexual health and pain management sectors. Its leading innovation is MED3000, a topic...

Futura Medical Earnings Call Summary

Earnings Call Date:Sep 30, 2025(Q2-2025)|% Change Since:-67.74%|Next Earnings Date:Apr 14, 2027
Earnings Call SentimentNegative

The earnings call reflected significant financial and operational challenges with revenue shortfalls, unexpected market performance, and inventory issues. While there are promising R&D developments, these are long-term. Immediate financial pressures and market challenges dominate the current outlook.

Positive Updates

R&D Developments
Futura is advancing two new products: Project Intense and WSD4000. Project Intense aims to enhance sensorial effects for men, with regulatory approval expected by the end of 2025. WSD4000 targets women's sexual response, with significant market potential, though it is expected to launch in the latter half of 2028.

Negative Updates

Revenue Shortfall
Revenues of just over GBP 1 million for H1 2025 fell significantly below expectations, with full-year sales now expected to be between GBP 1.3 million and GBP 1.4 million, far below the initial GBP 5 million projection.

Company Guidance

During the investor presentation call for Futura Medical plc, Interim CEO Alex Duggan provided guidance indicating that the company's full-year 2025 performance is expected to fall significantly below market expectations due to challenges in sustaining consumer uptake and lower-than-anticipated repeat sales. Despite launching in seven countries in H1, the initial strong trials did not translate into continued sales, affecting supply volumes and royalty streams. Angela Hildreth reported a revenue of just over GBP 1 million for the first half of 2025, with a gross profit of GBP 0.7 million, but also highlighted a GBP 0.49 million provision for inventory obsolescence. The company incurred an exceptional charge of GBP 3.6 million due to impairment of U.S. plant and equipment, contributing to a loss after tax of GBP 6.6 million. The adjusted loss after tax was GBP 1.9 million, with cash reserves at GBP 3.69 million at the period's end. Full-year sales for 2025 are now projected to be between GBP 1.3 million and GBP 1.4 million, with cash reserves reduced to GBP 2.7 million by the end of August. The company is actively exploring commercial and financing options to extend its cash runway, which currently runs into January 2026.

Futura Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:GYX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:SBTXGB:SBTX59NeutralGBP 12.31M-26.39-5.25%―95.16%85.60%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:POLBGB:POLB42NeutralGBP 44.66M-7.50-71.28%――31.58%
GB:AVCTGB:AVCT40UnderperformGBP 287.20M-6.47-1293.07%―――
GB:ARECGB:AREC33UnderperformGBP 35.11M155.003.75%―――
GB:OPTIGB:OPTI32UnderperformGBP 4.70M-1.10-77.85%―11.90%-2864.29%

* Healthcare Sector Average

Performance Comparison

0%100%200%DE:GYXGB:AVCTGB:OPTIGB:SBTXGB:POLBGB:ARECDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:GYX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:GYXFutura Medical0.010.000.00%
GB:AVCTAvacta Group plc59.00-22.00-27.16%
GB:OPTIOptiBiotix Health4.55-3.70-44.85%
GB:SBTXSkinBioTherapeutics plc4.75-10.75-69.35%
GB:POLBPoolbeg Pharma Ltd.5.851.8044.44%
GB:ARECArecor Therapeutics PLC77.503.504.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.